LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited, a next-generation point of care diagnostics company, today announced it has commenced commercial shipment of its point of care NT-proBNP ...

In people with no history of CV disease, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels can predict a higher risk of developing CV disease across various blood pressure and pulse pressure ...

Zomedica launches two canine assays for TRUFORMA, including NT-proBNP for heart disease and progesterone for breeding. The assays provide reference lab-level accuracy in-clinic, enhancing diagnostics ...

San Francisco, CA - Measurement of serum amino terminal fragment of prohormone brain-type natriuretic peptide (NT-proBNP) can add useful information to the standard risk assessment of people with ...

"HF algorithms are starting to recognize and include NT-proBNP in identifying stage B HF…Studies such as ours could provide insight and guidance as to when repeat measures may be useful. Future work ...

Please provide your email address to receive an email when new articles are posted on . NT-proBNP concentration is a strong predictor of ventricular arrhythmias among people with an implantable device ...

RARITAN, N.J. -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced the CE Mark of an enhanced version of its VITROS® NT-proBNP II assay, part of Ortho's expansive cardiac ...

San Francisco, CA - Patients with stable coronary disease could potentially avoid echocardiographic or nuclear studies of ventricular function if their serum natriuretic peptide levels are low, ...

In this new subanalysis of data from the Atherosclerosis Risk in the Communities study, investigators assessed the risk of incident heart failure (HF) or death by race and sex, as influenced by ...

Run on the highly portable LumiraDx Platform, the LumiraDx NT-proBNP test is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes. It is ...